Monthly Archives: October 2017

Pharma gives the middle finger to patients

KEY TAKEAWAY:Gilead, which recently acquired Kite Pharma in an all cash deal, said the list price for Yescarta, which is to be administered just once to each patient, would be $373,000. The cost is supposed to make us feel good because the price is well below that of the first drug in this new class such as $475,000 for Novartis’s  Kymriah.

Continue reading

Pharma not wholly to blame for opioid epidemic

According to the Atlantic “opioid abuse is rampant in states like Ohio, where paramedics are increasingly spending time responding to overdoses and where coroners’ offices are running out of room to store bodies. In 2012, there were 793 million doses of opioids prescribed in the state, enough to supply every man, woman, and child, with 68 pills each”.  But is pharma really to blame? Continue reading

Blaming big pharma for our poor health

According to CNN.com “The United States will not be escaping the obesity epidemic crisis anytime soon: Nearly 40% of adults and 19% of youth are obese, the highest rate the country has ever seen in all adults, according to research released Friday by the National Center for Health Statistics”.  So who is responsible for telling patients to lose weight? Continue reading

“Well, we did something” California’s pharma pricing bill

Ed Silverman at Pharmalot conducted a very revealing interview with California state senator Ed Hernandez, the Democratic legislator who “shepherded the California pharma pricing bill.”

Ed gamely tries to pin down Senator Hernandez on how exactly the bill will make a positive difference. Senator Hernandez seems unable to articulate any particular mechanism of action. His perspective appears to be: “Well, we did SOMETHING.”  They did something because pharma companies have, for the most part, been ignoring the outrage over the high prices of drugs.

Continue reading